Trevena, Inc. (Nasdaq: TRVN) made a significant announcement that its partner in China, Jiangsu Nhwa, has received formal approval from the National Medical Products Administration for OLINVYK, a medication for adults who require intravenous opioid analgesic for acute pain management. The approval marks a major milestone for the company as it expands its market reach. As a result, $TRVN is currently trading at $2.54 with a massive increase of 293.86%.

Immuron Limited (Nasdaq: IMRN) has received FDA approval for its new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) in collaboration with the US Naval Medical Research Center (NMRC). The FDA lifted the clinical hold on the Investigational New Drug application, allowing the NMRC to proceed with its plans to evaluate the efficacy of the hyperimmune product to prevent infectious diarrhea caused by Campylobacter and ETEC. This development has resulted in $IMRN trading at $2.53 with an increase of 35.35%.

Imperial Petroleum (Nasdaq: IMPP) has announced its unaudited financial and operating results for the first quarter of 2023, with CEO Harry Vafias commenting on the company's record revenues and profitability. The company has capitalized on the strong tanker market and utilized an average fleet of 10 vessels to produce a net income of $36 million in a single quarter, marking an increase of 17,750% compared to the same period last year. Furthermore, Imperial Petroleum has proposed the spin-off of 2 of its dry vessels to a separate company called C3is Inc., and has paid down all its debt while halting the issuance of new shares. These strategic moves have placed the company in an advantageous position to benefit from good market conditions, resulting in $IMPP trading at $3.09 with an increase of 28.75%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)